Market openADR
Autolus Therapeutics/$AUTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Ticker
$AUTL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
649
ISIN
US05280R1005
Website
AUTL Metrics
BasicAdvanced
$325M
-
-$0.89
-
-
Price and volume
Market cap
$325M
52-week high
$2.13
52-week low
$1.11
Average daily volume
2.4M
Financial strength
Current ratio
9.244
Interest coverage (TTM)
-28.76%
Management effectiveness
Return on assets (TTM)
-20.27%
Return on equity (TTM)
-49.97%
Valuation
Price to revenue (TTM)
36.035
Price to book
0.87
Price to tangible book (TTM)
0.87
Growth
Revenue change (TTM)
-14.16%
Earnings per share change (TTM)
-24.77%
3-year revenue growth (CAGR)
59.35%
3-year earnings per share growth (CAGR)
-21.39%
AUTL News
AllArticlesVideos
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
GlobeNewsWire·1 day ago
Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript
Seeking Alpha·4 days ago
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Autolus Therapeutics stock?
Autolus Therapeutics (AUTL) has a market cap of $325M as of May 15, 2025.
What is the P/E ratio for Autolus Therapeutics stock?
The price to earnings (P/E) ratio for Autolus Therapeutics (AUTL) stock is 0 as of May 15, 2025.
Does Autolus Therapeutics stock pay dividends?
No, Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Autolus Therapeutics dividend payment date?
Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Autolus Therapeutics?
Autolus Therapeutics (AUTL) does not currently have a Beta indicator.